Tiblio
Sign Up

EMBC

Embecta Corp
NASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES

Key Statistics

Market Cap
$560.22M
P/E Ratio
4.01
EPS
$2.36
Beta
1.10
52W High
$15.13
52W Low
$8.47
50-Day MA
$9.59
200-Day MA
$11.95
Dividend Yield
6.48%
Profit Margin
12.90%
Forward P/E
—
PEG Ratio
—

About Embecta Corp

Embecta Corp (EMBC) is a premier medical technology company specializing in innovative insulin delivery solutions for diabetes management. As a strategic spin-off from Becton, Dickinson and Company, Embecta utilizes state-of-the-art technologies and a diverse product portfolio, including insulin pens and syringes, to optimize patient care and improve health outcomes. With a strong commitment to operational excellence and a customer-centric approach, Embecta is well-positioned to seize growth opportunities in the rapidly evolving diabetes care market, aiming to enhance patient experiences while solidifying its leadership within the industry.

Official WebsiteUSAFY End: September

Fundamentals

Revenue (TTM)$1.08B
Gross Profit (TTM)$681.90M
EBITDA$366.70M
Operating Margin29.20%
Return on Equity0.00%
Return on Assets18.40%
Revenue/Share (TTM)$18.45
Book Value$-10.35
Price-to-Book2.61
Price-to-Sales (TTM)0.52
EV/Revenue1.612
EV/EBITDA5.10
Quarterly Earnings Growth (YoY)82.70%
Quarterly Revenue Growth (YoY)-0.30%
Shares Outstanding$59.22M
Float$58.30M
% Insiders1.69%
% Institutions101.21%

Historical Volatility

HV 10-Day
25.77%
HV 20-Day
30.07%
HV 30-Day
30.79%
HV 60-Day
41.37%
HV Rank
7.5%

Volatility is currently contracting

Analyst Ratings

Consensus ($16.67 target)
1
Buy
2
Hold
1
Strong Sell
Data last updated: 4/15/2026